[SCHEDULE 13G] Caris Life Sciences, Inc. SEC Filing
David D. Halbert and affiliated entities report substantial ownership in Caris Life Sciences. Mr. Halbert directly holds 1,881,294 shares and 2,000,000 fully vested options, and reports shared beneficial ownership of additional shares held by affiliated entities. The filing shows an aggregate of 124,906,296 shares, which the filer states represents 44.1% of the outstanding common stock.
The shared holdings include 101,261,532 shares held by Caris Halbert, L.P. and additional shares held by ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. The filing explains that voting and investment power flows through Caris Investment Management, LLC and two family trusts, and that the percentage figures are calculated based on 281,224,124 shares outstanding as reflected in the issuer's report plus 218,794 shares issued to Mr. Halbert in settlement of a restricted stock unit.
David D. Halbert e societ脿 collegate dichiarano una partecipazione significativa in Caris Life Sciences. Il sig. Halbert detiene direttamente 1.881.294 azioni e 2.000.000 opzioni completamente maturate, e dichiara la titolarit脿 condivisa di ulteriori azioni detenute da entit脿 affiliate. Il deposito riporta un totale aggregato di 124.906.296 azioni, che il dichiarante indica corrispondere al 44,1% del capitale sociale in circolazione.
Le partecipazioni comuni comprendono 101.261.532 azioni detenute da Caris Halbert, L.P. e ulteriori azioni detenute da ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. e Caris Investment III Ltd. Il deposito spiega che il potere di voto e di investimento scorre attraverso Caris Investment Management, LLC e due trust familiari, e che le percentuali sono calcolate sulla base di 281.224.124 azioni in circolazione indicate nel rapporto dell'emittente, pi霉 218.794 azioni emesse al sig. Halbert a fronte della liquidazione di una restricted stock unit.
David D. Halbert y entidades afiliadas informan una participaci贸n importante en Caris Life Sciences. El Sr. Halbert posee directamente 1.881.294 acciones y 2.000.000 opciones totalmente adquiridas, y notifica la propiedad beneficiaria compartida de acciones adicionales mantenidas por entidades afiliadas. La presentaci贸n muestra un total agregado de 124.906.296 acciones, que el declarante se帽ala representa el 44,1% del capital social en circulaci贸n.
Las participaciones compartidas incluyen 101.261.532 acciones mantenidas por Caris Halbert, L.P. y acciones adicionales en poder de ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. y Caris Investment III Ltd. La presentaci贸n explica que el poder de voto y de inversi贸n fluye a trav茅s de Caris Investment Management, LLC y dos fideicomisos familiares, y que los porcentajes se calculan sobre 281.224.124 acciones en circulaci贸n seg煤n consta en el informe del emisor, m谩s 218.794 acciones emitidas al Sr. Halbert en liquidaci贸n de una restricted stock unit.
David D. Halbert 氚� 瓿勳棿靷姅 Caris Life Sciences鞐� 雽�頃� 靸侂嫻頃� 歆�攵勳潉 氤搓碃頄堨姷雼堧嫟. Halbert 鞌姅 歆侅爲鞝侅溂搿� 1,881,294欤检檧 2,000,000臧滌潣 鞕勳爠 旆摑 鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 瓿勳棿靷皜 氤挫湢頃� 於旉皜 欤检嫕鞐� 雽�頃� 瓿惦彊 靾橃澋鞝� 靻岇湢毳� 鞁犼碃頃╇媹雼�. 鞝滌稖 靹滊鞐愲姅 頃╆硠 124,906,296欤�臧� 旮办灛霅橃柎 鞛堨溂氅�, 鞝滌稖鞚胳潃 鞚搓矁鞚� 氚滍枆 氤错喌欤检潣 44.1%鞐� 頃措嫻頃滊嫟瓿� 氇呾嫓頄堨姷雼堧嫟.
瓿惦彊 氤挫湢鞐愲姅 Caris Halbert, L.P.臧� 氤挫湢頃� 101,261,532欤�鞕� ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd.臧� 氤挫湢頃� 於旉皜 欤检嫕鞚� 韽暔霅╇媹雼�. 靹滊電� 鞚橁舶甓� 氚� 韴瀽 甓岉暅鞚� Caris Investment Management, LLC鞕� 霊� 臧滌潣 臧�臁� 鞁犿儊鞚� 韱淀暣 頄夓偓霅滊嫟瓿� 靹る獏頃橂┌, 牍勳湪鞚� 氚滍枆須岇偓鞚� 氤搓碃靹滌棎 旮办灛霅� 281,224,124欤�鞚� 氚滍枆欤检嫕 靾橃棎 攴缄卑頃� 瓿勳偘霅橃棃瓿� 鞐赴鞐� 鞝滍暅臁瓣贝攵�欤检嫕雼渼(RSU) 鞝曥偘鞙茧 Halbert 鞌棎瓴� 氚滍枆霅� 218,794欤�臧� 雿旐暣臁岆嫟瓿� 氚濏様鞀惦媹雼�.
David D. Halbert et des entit茅s affili茅es d茅clarent une participation importante dans Caris Life Sciences. M. Halbert d茅tient directement 1 881 294 actions et 2 000 000 d'options enti猫rement acquises, et d茅clare la propri茅t茅 b茅n茅ficiaire partag茅e d'actions suppl茅mentaires d茅tenues par des entit茅s affili茅es. Le d茅p么t indique un total agr茅g茅 de 124 906 296 actions, que le d茅clarant affirme repr茅senter 44,1 % des actions ordinaires en circulation.
Les d茅tentions conjointes comprennent 101 261 532 actions d茅tenues par Caris Halbert, L.P. ainsi que des actions suppl茅mentaires d茅tenues par ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. et Caris Investment III Ltd. Le d茅p么t explique que le pouvoir de vote et d'investissement s'exerce via Caris Investment Management, LLC et deux trusts familiaux, et que les pourcentages sont calcul茅s sur la base de 281 224 124 actions en circulation telles qu'indiqu茅es dans le rapport de l'茅metteur, plus 218 794 actions 茅mises 脿 M. Halbert en r猫glement d'une restricted stock unit.
David D. Halbert und verbundene Gesellschaften melden eine erhebliche Beteiligung an Caris Life Sciences. Herr Halbert h盲lt unmittelbar 1.881.294 Aktien und 2.000.000 voll ausge眉bte Optionen und meldet zudem anteilige wirtschaftliche Eigentumsrechte an weiteren von verbundenen Gesellschaften gehaltenen Aktien. Die Einreichung weist insgesamt 124.906.296 Aktien aus, die der Melder als 44,1% des ausstehenden Stammkapitals angibt.
Zu den gemeinsam gehaltenen Anteilen geh枚ren 101.261.532 Aktien, die von Caris Halbert, L.P. gehalten werden, sowie weitere Aktien, die von ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. und Caris Investment III Ltd. gehalten werden. Die Einreichung erl盲utert, dass Stimm- und Anlagebefugnisse 眉ber Caris Investment Management, LLC und zwei Familientrusts ausge眉bt werden und dass die Prozents盲tze auf der Grundlage von 281.224.124 ausstehenden Aktien berechnet wurden, wie im Bericht des Emittenten angegeben, zuz眉glich 218.794 Aktien, die Herrn Halbert zur Begleichung einer Restricted Stock Unit ausgegeben wurden.
- Aggregate beneficial ownership of 124,906,296 shares clearly disclosed
- Ownership percentage specified as 44.1% of common stock
- Detailed breakdown of sole versus shared voting and dispositive power, including 2,000,000 fully vested options
- Identification of affiliated holders (Caris Halbert, L.P.; ADAPT I Ltd.; Carisome I, L.P.; Caris Investment II Ltd.; Caris Investment III Ltd.) and governance roles (Caris Investment Management, LLC; family trusts)
- None.
Insights
TL;DR: Filing discloses concentrated ownership: Halbert-affiliated parties control 44.1% of Caris common stock.
The Schedule 13G reports that David D. Halbert directly owns 1,881,294 shares plus 2,000,000 fully vested options and, together with affiliated entities, beneficially owns a total of 124,906,296 shares or 44.1% of the class. The largest single affiliated holder is Caris Halbert, L.P., with 101,261,532 shares (36.0% reported for that entity). These figures are presented on a share-count basis using 281,224,124 shares outstanding plus 218,794 additional shares noted for a restricted stock settlement. For investors, the filing provides clarity on ownership scale and the legal vehicles through which voting and disposition power are held.
TL;DR: Disclosure outlines control structure and delegated voting/investment power across Halbert entities.
The statement identifies the governance chain: Caris Investment Management, LLC is the general partner for multiple entities and two family trusts are the general partner or managing general partner of other entities, with Mr. Halbert as managing member or trustee. The filing discloses which shares are sole-held by Mr. Halbert and which are shared via the affiliated entities, and it enumerates voting and dispositive power counts. This record-level transparency is material for understanding who holds voting influence over the issuer but does not itself include any proposed corporate actions.
David D. Halbert e societ脿 collegate dichiarano una partecipazione significativa in Caris Life Sciences. Il sig. Halbert detiene direttamente 1.881.294 azioni e 2.000.000 opzioni completamente maturate, e dichiara la titolarit脿 condivisa di ulteriori azioni detenute da entit脿 affiliate. Il deposito riporta un totale aggregato di 124.906.296 azioni, che il dichiarante indica corrispondere al 44,1% del capitale sociale in circolazione.
Le partecipazioni comuni comprendono 101.261.532 azioni detenute da Caris Halbert, L.P. e ulteriori azioni detenute da ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. e Caris Investment III Ltd. Il deposito spiega che il potere di voto e di investimento scorre attraverso Caris Investment Management, LLC e due trust familiari, e che le percentuali sono calcolate sulla base di 281.224.124 azioni in circolazione indicate nel rapporto dell'emittente, pi霉 218.794 azioni emesse al sig. Halbert a fronte della liquidazione di una restricted stock unit.
David D. Halbert y entidades afiliadas informan una participaci贸n importante en Caris Life Sciences. El Sr. Halbert posee directamente 1.881.294 acciones y 2.000.000 opciones totalmente adquiridas, y notifica la propiedad beneficiaria compartida de acciones adicionales mantenidas por entidades afiliadas. La presentaci贸n muestra un total agregado de 124.906.296 acciones, que el declarante se帽ala representa el 44,1% del capital social en circulaci贸n.
Las participaciones compartidas incluyen 101.261.532 acciones mantenidas por Caris Halbert, L.P. y acciones adicionales en poder de ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. y Caris Investment III Ltd. La presentaci贸n explica que el poder de voto y de inversi贸n fluye a trav茅s de Caris Investment Management, LLC y dos fideicomisos familiares, y que los porcentajes se calculan sobre 281.224.124 acciones en circulaci贸n seg煤n consta en el informe del emisor, m谩s 218.794 acciones emitidas al Sr. Halbert en liquidaci贸n de una restricted stock unit.
David D. Halbert 氚� 瓿勳棿靷姅 Caris Life Sciences鞐� 雽�頃� 靸侂嫻頃� 歆�攵勳潉 氤搓碃頄堨姷雼堧嫟. Halbert 鞌姅 歆侅爲鞝侅溂搿� 1,881,294欤检檧 2,000,000臧滌潣 鞕勳爠 旆摑 鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 瓿勳棿靷皜 氤挫湢頃� 於旉皜 欤检嫕鞐� 雽�頃� 瓿惦彊 靾橃澋鞝� 靻岇湢毳� 鞁犼碃頃╇媹雼�. 鞝滌稖 靹滊鞐愲姅 頃╆硠 124,906,296欤�臧� 旮办灛霅橃柎 鞛堨溂氅�, 鞝滌稖鞚胳潃 鞚搓矁鞚� 氚滍枆 氤错喌欤检潣 44.1%鞐� 頃措嫻頃滊嫟瓿� 氇呾嫓頄堨姷雼堧嫟.
瓿惦彊 氤挫湢鞐愲姅 Caris Halbert, L.P.臧� 氤挫湢頃� 101,261,532欤�鞕� ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd.臧� 氤挫湢頃� 於旉皜 欤检嫕鞚� 韽暔霅╇媹雼�. 靹滊電� 鞚橁舶甓� 氚� 韴瀽 甓岉暅鞚� Caris Investment Management, LLC鞕� 霊� 臧滌潣 臧�臁� 鞁犿儊鞚� 韱淀暣 頄夓偓霅滊嫟瓿� 靹る獏頃橂┌, 牍勳湪鞚� 氚滍枆須岇偓鞚� 氤搓碃靹滌棎 旮办灛霅� 281,224,124欤�鞚� 氚滍枆欤检嫕 靾橃棎 攴缄卑頃� 瓿勳偘霅橃棃瓿� 鞐赴鞐� 鞝滍暅臁瓣贝攵�欤检嫕雼渼(RSU) 鞝曥偘鞙茧 Halbert 鞌棎瓴� 氚滍枆霅� 218,794欤�臧� 雿旐暣臁岆嫟瓿� 氚濏様鞀惦媹雼�.
David D. Halbert et des entit茅s affili茅es d茅clarent une participation importante dans Caris Life Sciences. M. Halbert d茅tient directement 1 881 294 actions et 2 000 000 d'options enti猫rement acquises, et d茅clare la propri茅t茅 b茅n茅ficiaire partag茅e d'actions suppl茅mentaires d茅tenues par des entit茅s affili茅es. Le d茅p么t indique un total agr茅g茅 de 124 906 296 actions, que le d茅clarant affirme repr茅senter 44,1 % des actions ordinaires en circulation.
Les d茅tentions conjointes comprennent 101 261 532 actions d茅tenues par Caris Halbert, L.P. ainsi que des actions suppl茅mentaires d茅tenues par ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. et Caris Investment III Ltd. Le d茅p么t explique que le pouvoir de vote et d'investissement s'exerce via Caris Investment Management, LLC et deux trusts familiaux, et que les pourcentages sont calcul茅s sur la base de 281 224 124 actions en circulation telles qu'indiqu茅es dans le rapport de l'茅metteur, plus 218 794 actions 茅mises 脿 M. Halbert en r猫glement d'une restricted stock unit.
David D. Halbert und verbundene Gesellschaften melden eine erhebliche Beteiligung an Caris Life Sciences. Herr Halbert h盲lt unmittelbar 1.881.294 Aktien und 2.000.000 voll ausge眉bte Optionen und meldet zudem anteilige wirtschaftliche Eigentumsrechte an weiteren von verbundenen Gesellschaften gehaltenen Aktien. Die Einreichung weist insgesamt 124.906.296 Aktien aus, die der Melder als 44,1% des ausstehenden Stammkapitals angibt.
Zu den gemeinsam gehaltenen Anteilen geh枚ren 101.261.532 Aktien, die von Caris Halbert, L.P. gehalten werden, sowie weitere Aktien, die von ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd. und Caris Investment III Ltd. gehalten werden. Die Einreichung erl盲utert, dass Stimm- und Anlagebefugnisse 眉ber Caris Investment Management, LLC und zwei Familientrusts ausge眉bt werden und dass die Prozents盲tze auf der Grundlage von 281.224.124 ausstehenden Aktien berechnet wurden, wie im Bericht des Emittenten angegeben, zuz眉glich 218.794 Aktien, die Herrn Halbert zur Begleichung einer Restricted Stock Unit ausgegeben wurden.
FAQ
Who filed the Schedule 13G for Caris Life Sciences (CAI)?
How many shares does David D. Halbert beneficially own according to the filing?
What portion of the reported holdings are held by Caris Halbert, L.P. (CAI)?
Does the filing disclose any options or other instruments?
On what share base are the percentage calculations made?
